Quidel Corp (QDEL) 27.14 $QDEL
Quidel beats Street 3Q forecasts
Automated Insights - Tue Oct 21, 4:31PM CDT
SAN DIEGO (AP) _ Quidel Corp. (QDEL) on Tuesday reported a loss of $5.8 million in its third quarter.
QDEL: 27.14 (-0.38)
Quidel Reports Third Quarter 2014 Financial Results
Marketwired - Tue Oct 21, 3:10PM CDT
Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today financial results for the third quarter ended September 30, 2014.
QDEL: 27.14 (-0.38)
13.3% Return Seen to Date on SmarTrend Quidel Call (QDEL)
Comtex SmarTrend(R) - Mon Oct 20, 9:34AM CDT
SmarTrend identified an Uptrend for Quidel (NASDAQ:QDEL) on August 11th, 2014 at $24.92. In approximately 2 months, Quidel has returned 13.27% as of today's recent price of $28.22.
QDEL: 27.14 (-0.38)
Quidel wins US FDA clearance for Lyra Molecular PCR Assay for detection of Human Parainfluenza Viruses Types 1, 2 and 3
M2 - Thu Oct 16, 4:51AM CDT
Diagnostic testing company Quidel (NASDAQ:QDEL) reported on Wednesday the receipt of the 510(k) clearance from the US Food and Drug Administration (FDA) to market its Lyra Parainfluenza Assay, a real-time PCR test for the detection and identification of human parainfluenza virus (HPIV) infections.
QDEL: 27.14 (-0.38)
Quidel Receives FDA Clearance for Its Lyra(TM) Molecular PCR Assay for the Detection of Human Parainfluenza Viruses (HPIV), Types 1, 2 and 3
Marketwired - Wed Oct 15, 1:00PM CDT
Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it has received 510(k) clearance from the United States Food and Drug Administration (FDA) to market its Lyra Parainfluenza Assay, a real-time PCR test for the qualitative detection and identification of human parainfluenza virus (HPIV) infections for virus types 1, 2, or 3 viral RNA extracted from nasal swab and nasopharyngeal swab specimens.
QDEL: 27.14 (-0.38)
4 Stocks Rising on Unusual Volume
at The Street - Tue Oct 14, 8:28AM CDT
Often when above-average volume moves into an equity, it precedes a large spike in volatility.
BIS: 11.46 (-0.78), QDEL: 27.14 (-0.38), GLPW: 12.70 (+0.20), FRGI: 51.09 (+0.62)
Quidel passes US FDA's clearance for Lyra Molecular PCR Assay for the detection of adenovirus
M2 - Tue Oct 14, 6:17AM CDT
Diagnostic testing company Quidel (NASDAQ:QDEL) revealed on Monday the receipt of the 510(k) clearance from the US Food and Drug Administration (FDA) to market its Lyra Adenovirus Assay for the qualitative detection of human adenovirus (HAdV).
QDEL: 27.14 (-0.38)
Quidel Receives FDA Clearance for Its Lyra(R) Molecular PCR Assay for the Detection of Adenovirus
Marketwired - Mon Oct 13, 1:00PM CDT
Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it has received 510(k) clearance from the United States Food and Drug Administration (FDA) to market its Lyra Adenovirus Assay, a real-time PCR test for the qualitative detection of human adenovirus (HAdV) viral DNA isolated from nasal swab and nasopharyngeal swab specimens.
QDEL: 27.14 (-0.38)
Quidel to Hold Third Quarter 2014 Financial Results Conference Call on October 21, 2014
Marketwire - Mon Oct 06, 3:10PM CDT
Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, will release third quarter 2014 financial results after market close on Tuesday, October 21, 2014.
QDEL: 27.14 (-0.38)
Quidel Corp. (QDEL) in Focus: Stock Moves 6.73% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Sep 19, 8:21AM CDT
Quidel Corp. (QDEL) was a big mover last session, as the company saw its shares rise nearly 7% on the day.
ICUI: 70.19 (+0.04), CNAT: 7.12 (+0.05), QDEL: 27.14 (-0.38), ATRC: 15.44 (+0.19)
Nasdaq stocks posting largest percentage increases
AP - Thu Sep 18, 12:18PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
AMBA: 41.46 (+2.28), PRSC: 40.62 (+0.62), PERI: 5.82 (+0.05), RJET: 11.28 (+0.38), MSON: 10.19 (+0.42), QDEL: 27.14 (-0.38), ISRL: 131.99 (-11.99), TGTX: 10.09 (-0.01), RENT: 75.50 (+2.38), NYNY: 6.64 (-0.01), YRCW: 17.72 (+0.83), EMKR: 5.71 (+0.11), PODD: 38.58 (+1.15), AUXL: 31.12 (+0.53), APOG: 40.83 (+1.10), IDSY: 7.06 (+0.17)
Quidel to Present at Baird 2014 Health Care Conference
Marketwire - Fri Aug 22, 12:30PM CDT
Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cell-based virology assays and molecular diagnostic systems, announced today that it will present at the Baird 2014 Health Care Conference to be held at the New York Palace hotel in New York, NY on Wednesday, September 3, 2014.
QDEL: 27.14 (-0.38)
Quidel Earnings In Retrospect: Up 10.4% in the Last 20 Days (QDEL)
Comtex SmarTrend(R) - Mon Aug 11, 11:53AM CDT
20 days ago, on July 22nd, 2014, Quidel (NASDAQ:QDEL) reported its earnings. Analysts, on average, expected a loss of $0.11 per share on sales of $30.4 million. The company actually reported a loss of $0.10 per share on sales of $31.5 million, beating EPS estimates by $0.01 and beating revenue estimates by $1.1 million. Since the company's report, shares of Quidel have risen from $22.49 to $24.83, representing a gain of 10.4% in the past 20 days.
QDEL: 27.14 (-0.38)
Quidel Has Returned 15.2% Since SmarTrend Recommendation (QDEL)
Comtex SmarTrend(R) - Tue Aug 05, 11:06AM CDT
SmarTrend identified a Downtrend for Quidel (NASDAQ:QDEL) on February 3rd, 2014 at $28.70. In approximately 6 months, Quidel has returned 15.18% as of today's recent price of $24.34.
QDEL: 27.14 (-0.38)
5 Stocks Insiders Love Right Now
at The Street - Wed Jul 30, 10:34AM CDT
Insiders at these companies have been scooping up shares of their own stock lately.
T: 34.62 (+0.34), QDEL: 27.14 (-0.38), GLF: 29.87 (-0.58), SAEX: 6.91 (-0.09), CLB: 145.93 (+4.10)
Shares of QDEL Down 18.6% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Tue Jul 29, 10:03AM CDT
SmarTrend identified a Downtrend for Quidel (NASDAQ:QDEL) on February 3rd, 2014 at $28.70. In approximately 6 months, Quidel has returned 18.57% as of today's recent price of $23.37.
QDEL: 27.14 (-0.38)
Quidel passes US FDA's clearance to market molecular diagnostic test AmpliVue assay for Group A Strep
M2 - Tue Jul 29, 6:09AM CDT
Diagnostic testing company Quidel (NASDAQ:QDEL) disclosed on Monday the receipt of the US Food and Drug Administration's (FDA) approval to market its AmpliVue GAS Assay for the qualitative detection of Group A ?-hemolytic Streptococcus (Streptococcus pyogenes) nucleic acids isolated from throat swab specimens.
QDEL: 27.14 (-0.38)
Quidel Receives FDA Clearance for Its Hand-Held Molecular Diagnostic Test for Group A Strep
Marketwire - Mon Jul 28, 8:01AM CDT
Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it has received clearance from the United States Food and Drug Administration (FDA) to market its AmpliVue GAS Assay for the qualitative detection of Group A β-hemolytic Streptococcus (Streptococcus pyogenes) nucleic acids isolated from throat swab specimens obtained from patients with signs and symptoms of pharyngitis, such as sore throat.
QDEL: 27.14 (-0.38)
Quidel (QDEL) Falls: Stock Goes Down 7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jul 25, 7:59AM CDT
Quidel has seen negative earnings estimate revisions for the current year along with a significant decline in its share price for the past one day
CSII: 27.79 (+0.70), CFN: 56.67 (+0.20), QDEL: 27.14 (-0.38), ALR: 37.98 (+0.67)
Quidel beats Street 3Q forecasts
Automated Insights - Tue Oct 21, 4:31PM CDT
SAN DIEGO (AP) _ Quidel Corp. (QDEL) on Tuesday reported a loss of $5.8 million in its third quarter.
QDEL: 27.14 (-0.38)
Quidel Reports Third Quarter 2014 Financial Results
Marketwired - Tue Oct 21, 3:10PM CDT
Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today financial results for the third quarter ended September 30, 2014.
QDEL: 27.14 (-0.38)
13.3% Return Seen to Date on SmarTrend Quidel Call (QDEL)
Comtex SmarTrend(R) - Mon Oct 20, 9:34AM CDT
SmarTrend identified an Uptrend for Quidel (NASDAQ:QDEL) on August 11th, 2014 at $24.92. In approximately 2 months, Quidel has returned 13.27% as of today's recent price of $28.22.
QDEL: 27.14 (-0.38)
Quidel wins US FDA clearance for Lyra Molecular PCR Assay for detection of Human Parainfluenza Viruses Types 1, 2 and 3
M2 - Thu Oct 16, 4:51AM CDT
Diagnostic testing company Quidel (NASDAQ:QDEL) reported on Wednesday the receipt of the 510(k) clearance from the US Food and Drug Administration (FDA) to market its Lyra Parainfluenza Assay, a real-time PCR test for the detection and identification of human parainfluenza virus (HPIV) infections.
QDEL: 27.14 (-0.38)
Quidel Receives FDA Clearance for Its Lyra(TM) Molecular PCR Assay for the Detection of Human Parainfluenza Viruses (HPIV), Types 1, 2 and 3
Marketwired - Wed Oct 15, 1:00PM CDT
Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it has received 510(k) clearance from the United States Food and Drug Administration (FDA) to market its Lyra Parainfluenza Assay, a real-time PCR test for the qualitative detection and identification of human parainfluenza virus (HPIV) infections for virus types 1, 2, or 3 viral RNA extracted from nasal swab and nasopharyngeal swab specimens.
QDEL: 27.14 (-0.38)
4 Stocks Rising on Unusual Volume
at The Street - Tue Oct 14, 8:28AM CDT
Often when above-average volume moves into an equity, it precedes a large spike in volatility.
BIS: 11.46 (-0.78), QDEL: 27.14 (-0.38), GLPW: 12.70 (+0.20), FRGI: 51.09 (+0.62)
Quidel passes US FDA's clearance for Lyra Molecular PCR Assay for the detection of adenovirus
M2 - Tue Oct 14, 6:17AM CDT
Diagnostic testing company Quidel (NASDAQ:QDEL) revealed on Monday the receipt of the 510(k) clearance from the US Food and Drug Administration (FDA) to market its Lyra Adenovirus Assay for the qualitative detection of human adenovirus (HAdV).
QDEL: 27.14 (-0.38)
Quidel Receives FDA Clearance for Its Lyra(R) Molecular PCR Assay for the Detection of Adenovirus
Marketwired - Mon Oct 13, 1:00PM CDT
Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it has received 510(k) clearance from the United States Food and Drug Administration (FDA) to market its Lyra Adenovirus Assay, a real-time PCR test for the qualitative detection of human adenovirus (HAdV) viral DNA isolated from nasal swab and nasopharyngeal swab specimens.
QDEL: 27.14 (-0.38)
Quidel to Hold Third Quarter 2014 Financial Results Conference Call on October 21, 2014
Marketwire - Mon Oct 06, 3:10PM CDT
Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, will release third quarter 2014 financial results after market close on Tuesday, October 21, 2014.
QDEL: 27.14 (-0.38)
Quidel Corp. (QDEL) in Focus: Stock Moves 6.73% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Sep 19, 8:21AM CDT
Quidel Corp. (QDEL) was a big mover last session, as the company saw its shares rise nearly 7% on the day.
ICUI: 70.19 (+0.04), CNAT: 7.12 (+0.05), QDEL: 27.14 (-0.38), ATRC: 15.44 (+0.19)
Nasdaq stocks posting largest percentage increases
AP - Thu Sep 18, 12:18PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
AMBA: 41.46 (+2.28), PRSC: 40.62 (+0.62), PERI: 5.82 (+0.05), RJET: 11.28 (+0.38), MSON: 10.19 (+0.42), QDEL: 27.14 (-0.38), ISRL: 131.99 (-11.99), TGTX: 10.09 (-0.01), RENT: 75.50 (+2.38), NYNY: 6.64 (-0.01), YRCW: 17.72 (+0.83), EMKR: 5.71 (+0.11), PODD: 38.58 (+1.15), AUXL: 31.12 (+0.53), APOG: 40.83 (+1.10), IDSY: 7.06 (+0.17)
Quidel to Present at Baird 2014 Health Care Conference
Marketwire - Fri Aug 22, 12:30PM CDT
Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cell-based virology assays and molecular diagnostic systems, announced today that it will present at the Baird 2014 Health Care Conference to be held at the New York Palace hotel in New York, NY on Wednesday, September 3, 2014.
QDEL: 27.14 (-0.38)
Quidel Earnings In Retrospect: Up 10.4% in the Last 20 Days (QDEL)
Comtex SmarTrend(R) - Mon Aug 11, 11:53AM CDT
20 days ago, on July 22nd, 2014, Quidel (NASDAQ:QDEL) reported its earnings. Analysts, on average, expected a loss of $0.11 per share on sales of $30.4 million. The company actually reported a loss of $0.10 per share on sales of $31.5 million, beating EPS estimates by $0.01 and beating revenue estimates by $1.1 million. Since the company's report, shares of Quidel have risen from $22.49 to $24.83, representing a gain of 10.4% in the past 20 days.
QDEL: 27.14 (-0.38)
Quidel Has Returned 15.2% Since SmarTrend Recommendation (QDEL)
Comtex SmarTrend(R) - Tue Aug 05, 11:06AM CDT
SmarTrend identified a Downtrend for Quidel (NASDAQ:QDEL) on February 3rd, 2014 at $28.70. In approximately 6 months, Quidel has returned 15.18% as of today's recent price of $24.34.
QDEL: 27.14 (-0.38)
5 Stocks Insiders Love Right Now
at The Street - Wed Jul 30, 10:34AM CDT
Insiders at these companies have been scooping up shares of their own stock lately.
T: 34.62 (+0.34), QDEL: 27.14 (-0.38), GLF: 29.87 (-0.58), SAEX: 6.91 (-0.09), CLB: 145.93 (+4.10)
Shares of QDEL Down 18.6% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Tue Jul 29, 10:03AM CDT
SmarTrend identified a Downtrend for Quidel (NASDAQ:QDEL) on February 3rd, 2014 at $28.70. In approximately 6 months, Quidel has returned 18.57% as of today's recent price of $23.37.
QDEL: 27.14 (-0.38)
Quidel passes US FDA's clearance to market molecular diagnostic test AmpliVue assay for Group A Strep
M2 - Tue Jul 29, 6:09AM CDT
Diagnostic testing company Quidel (NASDAQ:QDEL) disclosed on Monday the receipt of the US Food and Drug Administration's (FDA) approval to market its AmpliVue GAS Assay for the qualitative detection of Group A ?-hemolytic Streptococcus (Streptococcus pyogenes) nucleic acids isolated from throat swab specimens.
QDEL: 27.14 (-0.38)
Quidel Receives FDA Clearance for Its Hand-Held Molecular Diagnostic Test for Group A Strep
Marketwire - Mon Jul 28, 8:01AM CDT
Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it has received clearance from the United States Food and Drug Administration (FDA) to market its AmpliVue GAS Assay for the qualitative detection of Group A β-hemolytic Streptococcus (Streptococcus pyogenes) nucleic acids isolated from throat swab specimens obtained from patients with signs and symptoms of pharyngitis, such as sore throat.
QDEL: 27.14 (-0.38)
Quidel (QDEL) Falls: Stock Goes Down 7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jul 25, 7:59AM CDT
Quidel has seen negative earnings estimate revisions for the current year along with a significant decline in its share price for the past one day
CSII: 27.79 (+0.70), CFN: 56.67 (+0.20), QDEL: 27.14 (-0.38), ALR: 37.98 (+0.67)
